{"pmid":32489751,"pmcid":"PMC7255538","title":"Managing Acute Portal Hypertensive Gastropathy Bleed During the Time of COVID-19 Pandemic: Novelty or Necessity?","text":["Managing Acute Portal Hypertensive Gastropathy Bleed During the Time of COVID-19 Pandemic: Novelty or Necessity?","Acute bleeding from portal hypertensive gastropathy (PHG) is an extremely rare event in the natural history of cirrhosis. The treatment recommendations include portal pressure reduction strategies including pharmacotherapy with vasoactive agents and beta-blockers and interventional strategies such as transjugular intrahepatic portosystemic shunt placement. In this report, we present the case of a patient with cirrhosis in whom acute PHG-related bleed was managed with endoscopic band ligation, a therapeutic modality which has not been described in current literature. Our decision to re-purpose a technique for variceal bleeding stems from the fact that during the ongoing COVID-19 pandemic, the technical assistance, resource availability, and sourcing of materials that were required for us to follow recommended management guidelines for acute PHG-related bleed was severely affected due to imposed lockdown between districts and states.","Cureus","Philips, Cyriac A","Kumbar, Sandeep","Ahamed, Rizwan","Augustine, Philip","32489751"],"abstract":["Acute bleeding from portal hypertensive gastropathy (PHG) is an extremely rare event in the natural history of cirrhosis. The treatment recommendations include portal pressure reduction strategies including pharmacotherapy with vasoactive agents and beta-blockers and interventional strategies such as transjugular intrahepatic portosystemic shunt placement. In this report, we present the case of a patient with cirrhosis in whom acute PHG-related bleed was managed with endoscopic band ligation, a therapeutic modality which has not been described in current literature. Our decision to re-purpose a technique for variceal bleeding stems from the fact that during the ongoing COVID-19 pandemic, the technical assistance, resource availability, and sourcing of materials that were required for us to follow recommended management guidelines for acute PHG-related bleed was severely affected due to imposed lockdown between districts and states."],"journal":"Cureus","authors":["Philips, Cyriac A","Kumbar, Sandeep","Ahamed, Rizwan","Augustine, Philip"],"date":"2020-06-04T11:00:00Z","year":2020,"_id":"32489751","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.7759/cureus.8333","keywords":["banding","cirrhosis","coronavirus","covid","endoscopy","evl","gi bleeding","phg"],"topics":["Prevention"],"weight":1,"_version_":1668623433709125633,"score":9.490897,"similar":[{"pmid":32289878,"title":"Emergency endoscopic variceal band ligation in a COVID-19 patient presented with hematemesis while on mechanical ventilation.","text":["Emergency endoscopic variceal band ligation in a COVID-19 patient presented with hematemesis while on mechanical ventilation.","COVID-19, caused by severe acute respiratory syndrome coronavirus (SARS-CoV-2), is now a global pandemic with serious health consequences. Currently, many strict control measures are applied in health care settings, including endoscopy units, in order to limit virus spread. Several recommendations called to limit endoscopic procedures to emergent endoscopies; however, several uncertainties still existing concerning patient safety, protective measures, and infection control methods in emergency endoscopic settings. In this case report, we present a case of successful endoscopic band ligation for bleeding esophageal varices in man with COVID-19 disease who presented with an acute attack of hematemesis while on mechanical ventilation (MV). Esophago- gastroduodenoscopy was performed in the ICU room after preparing the setting, and revealed large, risky esophageal varices. Endoscopic band ligation was done with successful control of bleeding. Third-level measures of medical protection were applied for the participating medical personnel, and patient monitoring was kept all through the procedure. After the procedure, the bleeding stopped, and the patient was vitally stable and conscious. We conclude that emergency endoscopic interventions could be performed safely with appropriate arrangements in patients with confirmed COVID-19 on mechanical ventilation.","Dig Endosc","El Kassas, Mohamed","Al Shafie, Ahmad","Abdel Hameed, Abo Seif","Mahdi, Mamdouh","32289878"],"abstract":["COVID-19, caused by severe acute respiratory syndrome coronavirus (SARS-CoV-2), is now a global pandemic with serious health consequences. Currently, many strict control measures are applied in health care settings, including endoscopy units, in order to limit virus spread. Several recommendations called to limit endoscopic procedures to emergent endoscopies; however, several uncertainties still existing concerning patient safety, protective measures, and infection control methods in emergency endoscopic settings. In this case report, we present a case of successful endoscopic band ligation for bleeding esophageal varices in man with COVID-19 disease who presented with an acute attack of hematemesis while on mechanical ventilation (MV). Esophago- gastroduodenoscopy was performed in the ICU room after preparing the setting, and revealed large, risky esophageal varices. Endoscopic band ligation was done with successful control of bleeding. Third-level measures of medical protection were applied for the participating medical personnel, and patient monitoring was kept all through the procedure. After the procedure, the bleeding stopped, and the patient was vitally stable and conscious. We conclude that emergency endoscopic interventions could be performed safely with appropriate arrangements in patients with confirmed COVID-19 on mechanical ventilation."],"journal":"Dig Endosc","authors":["El Kassas, Mohamed","Al Shafie, Ahmad","Abdel Hameed, Abo Seif","Mahdi, Mamdouh"],"date":"2020-04-15T11:00:00Z","year":2020,"_id":"32289878","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1111/den.13694","keywords":["covid-19","hematemesis","band ligation","endoscopic intervention","mechanical ventilation"],"topics":["Prevention"],"weight":1,"_version_":1666138491359068160,"score":340.68933},{"pmid":32440857,"title":"Clinical course of COVID-19 in patients with pre-existing decompensated cirrhosis: initial report from China.","text":["Clinical course of COVID-19 in patients with pre-existing decompensated cirrhosis: initial report from China.","BACKGROUND: The clinical characteristics and disease course in COVID-19 patients with pre-existing decompensated cirrhosis has not been described so far. METHODS: In this case series, we report three patients with confirmed COVID-19 and pre-existing decompensated cirrhosis from three hospitals in Hubei, the epicenter of the outbreak in China. RESULT: Patient 1 was a 53-year-old man with hepatitis B virus-related cirrhosis, portal hypertension, and ascites. Though receiving intensive support, he died of irreversible multiple organ dysfunction syndrome 48 days after the onset of the illness. Patient 2 was a 75-year-old woman with a history of schistosomiasis-related cirrhosis, portal hypertension, and ascites. Her family members requested that invasive rescue measures not be undertaken, and she died of acute respiratory distress syndrome 40 days after presenting with COVID-19 infection. Patient 3 was an 87-year-old man with alcohol-related cirrhosis, portal hypertension, and esophageal variceal hemorrhage. He was discharged from the hospital 29 days after illness onset. CONCLUSION: The case series raise the possibility that decompensated cirrhosis may be a risk factor for a poor outcome in patients with COVID-19.","Hepatol Int","Qi, Xiaolong","Wang, Jitao","Li, Xinyu","Wang, Zhengyan","Liu, Yanna","Yang, Hua","Li, Xiaodan","Shi, Jindong","Xiang, Huihua","Liu, Tao","Kawada, Norifumi","Maruyama, Hitoshi","Jiang, Zicheng","Wang, Fengmei","Takehara, Tetsuo","Rockey, Don C","Sarin, Shiv Kumar","32440857"],"abstract":["BACKGROUND: The clinical characteristics and disease course in COVID-19 patients with pre-existing decompensated cirrhosis has not been described so far. METHODS: In this case series, we report three patients with confirmed COVID-19 and pre-existing decompensated cirrhosis from three hospitals in Hubei, the epicenter of the outbreak in China. RESULT: Patient 1 was a 53-year-old man with hepatitis B virus-related cirrhosis, portal hypertension, and ascites. Though receiving intensive support, he died of irreversible multiple organ dysfunction syndrome 48 days after the onset of the illness. Patient 2 was a 75-year-old woman with a history of schistosomiasis-related cirrhosis, portal hypertension, and ascites. Her family members requested that invasive rescue measures not be undertaken, and she died of acute respiratory distress syndrome 40 days after presenting with COVID-19 infection. Patient 3 was an 87-year-old man with alcohol-related cirrhosis, portal hypertension, and esophageal variceal hemorrhage. He was discharged from the hospital 29 days after illness onset. CONCLUSION: The case series raise the possibility that decompensated cirrhosis may be a risk factor for a poor outcome in patients with COVID-19."],"journal":"Hepatol Int","authors":["Qi, Xiaolong","Wang, Jitao","Li, Xinyu","Wang, Zhengyan","Liu, Yanna","Yang, Hua","Li, Xiaodan","Shi, Jindong","Xiang, Huihua","Liu, Tao","Kawada, Norifumi","Maruyama, Hitoshi","Jiang, Zicheng","Wang, Fengmei","Takehara, Tetsuo","Rockey, Don C","Sarin, Shiv Kumar"],"date":"2020-05-23T11:00:00Z","year":2020,"_id":"32440857","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1007/s12072-020-10051-z","keywords":["advanced chronic liver disease","covid-19","clinical characteristics"],"locations":["Hubei","China","China"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["Alcohols"],"topics":["Case Report"],"weight":1,"_version_":1667523504831987712,"score":315.24927},{"pmid":32408356,"title":"Decline in acute upper gastrointestinal bleeding during Covid-19 pandemic after lockdown in Austria.","text":["Decline in acute upper gastrointestinal bleeding during Covid-19 pandemic after lockdown in Austria.","Background and study aims COVID-19 disease has rapidly spread all over the world. The Austrian government has implemented a lockdown to contain further spread of this disease on March 16th. We investigated the effects of lockdown on acute upper gastrointestinal (GI) bleeding in Austria. Patients and methods We contacted 98 Austrian hospitals performing emergency endoscopies. The hospitals were asked to report upper GI endoscopies performed because of recent hematemesis, melena, or both and exhibiting endoscopically visible signs of bleeding. Investigated time points included three weeks before and after lockdown. Results 61% of Austrian hospitals and importantly all major state hospitals responded. 575 upper GI bleedings occurred in the three weeks before and 341 after lockdown (40.7% reduction). When comparing the first and last calendar week of investigation we observed an almost 55% decline in nonvariceal bleeding events (calendar week 9 versus 14: 196 versus 89) whereas rates of variceal hemorrhage did not change (calendar week 9 versus 14: 17 versus 15). Conclusions National lockdown resulted in a dramatic decrease in upper gastrointestinal bleeding events.","Endoscopy","Schmiderer, Andreas","Schwaighofer, Hubert","Niederreiter, Lukas","Profanter, Christoph","Steinle, Hartmut","Ziachehabi, Alexander","Tilg, Herbert","32408356"],"abstract":["Background and study aims COVID-19 disease has rapidly spread all over the world. The Austrian government has implemented a lockdown to contain further spread of this disease on March 16th. We investigated the effects of lockdown on acute upper gastrointestinal (GI) bleeding in Austria. Patients and methods We contacted 98 Austrian hospitals performing emergency endoscopies. The hospitals were asked to report upper GI endoscopies performed because of recent hematemesis, melena, or both and exhibiting endoscopically visible signs of bleeding. Investigated time points included three weeks before and after lockdown. Results 61% of Austrian hospitals and importantly all major state hospitals responded. 575 upper GI bleedings occurred in the three weeks before and 341 after lockdown (40.7% reduction). When comparing the first and last calendar week of investigation we observed an almost 55% decline in nonvariceal bleeding events (calendar week 9 versus 14: 196 versus 89) whereas rates of variceal hemorrhage did not change (calendar week 9 versus 14: 17 versus 15). Conclusions National lockdown resulted in a dramatic decrease in upper gastrointestinal bleeding events."],"journal":"Endoscopy","authors":["Schmiderer, Andreas","Schwaighofer, Hubert","Niederreiter, Lukas","Profanter, Christoph","Steinle, Hartmut","Ziachehabi, Alexander","Tilg, Herbert"],"date":"2020-05-15T11:00:00Z","year":2020,"_id":"32408356","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1055/a-1178-4656","locations":["Austrian","Austria","Austrian","melena","Austrian","Austria"],"countries":["Austria"],"countries_codes":["AUT|Austria"],"topics":["Prevention"],"weight":1,"_version_":1666802845608837121,"score":295.63586},{"pmid":32424429,"title":"Neurologically Devastating Intraparenchymal Hemorrhage in COVID-19 Patients on Extracorporeal Membrane Oxygenation: A Case Series.","text":["Neurologically Devastating Intraparenchymal Hemorrhage in COVID-19 Patients on Extracorporeal Membrane Oxygenation: A Case Series.","BACKGROUND AND IMPORTANCE: Extracorporeal membrane oxygenation (ECMO) represents a life-saving therapy in cases of refractory hypoxia and has been utilized in patients suffering from the most severe forms of coronavirus disease 2019 (COVID-19). A strikingly high mortality rate of 94% was described in early reports of patients with COVID-19 transitioned to ECMO. Later case reports and series demonstrating successful recovery from COVID-19 after ECMO have revived interest in this therapeutic modality, including the recent approval of ECMO for COVID-19 patients by the Food and Drug Administration (FDA). Here, we present the first reports of devastating intracranial hemorrhage as a complication of veno-venous (VV) ECMO in two COVID-19 patients. CLINICAL PRESENTATION: We performed a retrospective analysis of 2 cases of devastating intracranial hemorrhage in patients on VV-ECMO for the treatment of COVID-19. Collected data included clinical history, laboratory results, treatment, and review of all available imaging. Both patients demonstrated activated partial thromboplastin times (aPTT) within an appropriate therapeutic range. No risk factors that clearly predicted likelihood of this complication were identified. CONCLUSION: Understanding the complications of ECMO in this cohort and developing therapeutic algorithms to aid in optimal patient selection will be critical in the limited resource setting experienced as a result of global pandemic. We propose the use of head computed tomography (CT) to identify devastating neurological complications as early as possible, aiding in the resource allocation of ECMO machines to the most appropriately selected patients.","Neurosurgery","Heman-Ackah, Sabrina M","Su, YouRong Sophie","Spadola, Michael","Petrov, Dmitriy","Chen, H Isaac","Schuster, James","Lucas, Timothy","32424429"],"abstract":["BACKGROUND AND IMPORTANCE: Extracorporeal membrane oxygenation (ECMO) represents a life-saving therapy in cases of refractory hypoxia and has been utilized in patients suffering from the most severe forms of coronavirus disease 2019 (COVID-19). A strikingly high mortality rate of 94% was described in early reports of patients with COVID-19 transitioned to ECMO. Later case reports and series demonstrating successful recovery from COVID-19 after ECMO have revived interest in this therapeutic modality, including the recent approval of ECMO for COVID-19 patients by the Food and Drug Administration (FDA). Here, we present the first reports of devastating intracranial hemorrhage as a complication of veno-venous (VV) ECMO in two COVID-19 patients. CLINICAL PRESENTATION: We performed a retrospective analysis of 2 cases of devastating intracranial hemorrhage in patients on VV-ECMO for the treatment of COVID-19. Collected data included clinical history, laboratory results, treatment, and review of all available imaging. Both patients demonstrated activated partial thromboplastin times (aPTT) within an appropriate therapeutic range. No risk factors that clearly predicted likelihood of this complication were identified. CONCLUSION: Understanding the complications of ECMO in this cohort and developing therapeutic algorithms to aid in optimal patient selection will be critical in the limited resource setting experienced as a result of global pandemic. We propose the use of head computed tomography (CT) to identify devastating neurological complications as early as possible, aiding in the resource allocation of ECMO machines to the most appropriately selected patients."],"journal":"Neurosurgery","authors":["Heman-Ackah, Sabrina M","Su, YouRong Sophie","Spadola, Michael","Petrov, Dmitriy","Chen, H Isaac","Schuster, James","Lucas, Timothy"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32424429","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1093/neuros/nyaa198","keywords":["covid-19","extracorporeal membrane oxygenation","intracranial hemorrhage","intraparenchymal hemorrhage","patient selection","resource allocation","sars-cov-2"],"locations":["optimal"],"topics":["Case Report"],"weight":1,"_version_":1667252837775572992,"score":180.267},{"pmid":32492712,"title":"COVID and Coagulation: Bleeding and Thrombotic Manifestations of SARS-CoV2 Infection.","text":["COVID and Coagulation: Bleeding and Thrombotic Manifestations of SARS-CoV2 Infection.","Patients with coronavirus disease 2019 (COVID-19) have elevated D-dimer levels. Early reports describe high venous thromboembolism (VTE) and disseminated intravascular coagulation (DIC) rates, but data are limited. This multicenter, retrospective study described the rate and severity of hemostatic and thrombotic complications of 400 hospital-admitted COVID-19 patients (144 critically ill) primarily receiving standard-dose prophylactic anticoagulation. Coagulation and inflammatory parameters were compared between patients with and without coagulation-associated complications. Multivariable logistic models examined the utility of these markers in predicting coagulation-associated complications, critical illness, and death. The radiographically-confirmed VTE rate was 4.8% (95% CI, 2.9-7.3%) and the overall thrombotic complication rate was 9.5% (6.8-12.8%). The overall and major bleeding rates were 4.8% (2.9-7.3%) and 2.3% (1.0-4.2%). In the critically ill, radiographically-confirmed VTE and major bleeding rates were 7.6% (3.9-13.3%) and 5.6% (2.4-10.7%). Elevated D-dimer at initial presentation was predictive of coagulation-associated complications during hospitalization [D-dimer >2,500 ng/mL, adjusted OR for thrombosis, 6.79 (2.39-19.30), adjusted OR for bleeding, 3.56 (1.01-12.66)], critical illness, and death. Additional markers at initial presentation predictive of thrombosis during hospitalization included platelet count >450x109/L [adjusted OR, 3.56 (1.27-9.97)], C-reactive protein (CRP) >100 mg/L [adjusted OR, 2.71 (1.26-5.86)], and erythrocyte sedimentation rate >40 mm/h [adjusted OR, 2.64 (1.07-6.51)]. ESR, CRP, fibrinogen, ferritin, and procalcitonin were higher in patients with thrombotic complications than those without. DIC, clinically-relevant thrombocytopenia, and reduced fibrinogen were rare and were associated with significant bleeding manifestations. Given the observed bleeding rates, randomized trials are needed to determine any potential benefit of intensified anticoagulant prophylaxis in COVID-19 patients.","Blood","Al-Samkari, Hanny","Karp Leaf, Rebecca S","Dzik, Walter H","Carlson, Jonathan Ct","Fogerty, Annemarie E","Waheed, Anem","Goodarzi, Katayoon","Bendapudi, Pavan","Bornikova, Larissa","Gupta, Shruti","Leaf, David","Kuter, David J","Rosovsky, Rachel P","32492712"],"abstract":["Patients with coronavirus disease 2019 (COVID-19) have elevated D-dimer levels. Early reports describe high venous thromboembolism (VTE) and disseminated intravascular coagulation (DIC) rates, but data are limited. This multicenter, retrospective study described the rate and severity of hemostatic and thrombotic complications of 400 hospital-admitted COVID-19 patients (144 critically ill) primarily receiving standard-dose prophylactic anticoagulation. Coagulation and inflammatory parameters were compared between patients with and without coagulation-associated complications. Multivariable logistic models examined the utility of these markers in predicting coagulation-associated complications, critical illness, and death. The radiographically-confirmed VTE rate was 4.8% (95% CI, 2.9-7.3%) and the overall thrombotic complication rate was 9.5% (6.8-12.8%). The overall and major bleeding rates were 4.8% (2.9-7.3%) and 2.3% (1.0-4.2%). In the critically ill, radiographically-confirmed VTE and major bleeding rates were 7.6% (3.9-13.3%) and 5.6% (2.4-10.7%). Elevated D-dimer at initial presentation was predictive of coagulation-associated complications during hospitalization [D-dimer >2,500 ng/mL, adjusted OR for thrombosis, 6.79 (2.39-19.30), adjusted OR for bleeding, 3.56 (1.01-12.66)], critical illness, and death. Additional markers at initial presentation predictive of thrombosis during hospitalization included platelet count >450x109/L [adjusted OR, 3.56 (1.27-9.97)], C-reactive protein (CRP) >100 mg/L [adjusted OR, 2.71 (1.26-5.86)], and erythrocyte sedimentation rate >40 mm/h [adjusted OR, 2.64 (1.07-6.51)]. ESR, CRP, fibrinogen, ferritin, and procalcitonin were higher in patients with thrombotic complications than those without. DIC, clinically-relevant thrombocytopenia, and reduced fibrinogen were rare and were associated with significant bleeding manifestations. Given the observed bleeding rates, randomized trials are needed to determine any potential benefit of intensified anticoagulant prophylaxis in COVID-19 patients."],"journal":"Blood","authors":["Al-Samkari, Hanny","Karp Leaf, Rebecca S","Dzik, Walter H","Carlson, Jonathan Ct","Fogerty, Annemarie E","Waheed, Anem","Goodarzi, Katayoon","Bendapudi, Pavan","Bornikova, Larissa","Gupta, Shruti","Leaf, David","Kuter, David J","Rosovsky, Rachel P"],"date":"2020-06-04T11:00:00Z","year":2020,"_id":"32492712","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1182/blood.2020006520","topics":["Treatment","Diagnosis"],"weight":1,"_version_":1668623433552887808,"score":179.04231}]}